– Reuters
Synaptogenix Announces Peer-Reviewed Publication Of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, And Persistent Benefits Of Bryostatin-1 in Advanced Alzheimer’s Disease
Bryostatin-1 benefits in severe Alzheimer's disease patients were statistically significant with respect to placebo at p < 0.007NEW YORK, Sept. 26, 2023 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX)
